MyopiaBRIGHT LIGHTNCT07923019
BRIGHT-LIGHT: Studying Red Light Therapy for Severe Short-Sightedness or Short-Sightedness That Worsens Despite Standard Treatment
A study testing Repeated low-level red-light (RLRL) therapy and Continued existing myopia treatment strategy in people with Myopia and Myopia Progressing, run by Singapore National Eye Centre at 2 sites in Singapore.
Trial summary
Some children's short-sightedness (myopia) continues to worsen despite treatments such as atropine eye drops, myopia-control spectacles or contact lenses. These children may be at greater risk of developing severe short-sightedness and related eye problems later in life. Read more about this study
- Who is it for?
- Ages 8 to 16 years
- Conditions the study is for
- Myopia, Myopia Progressing, Myopia Progression
- What is being tested?
- Repeated low-level red-light (RLRL) therapy and Continued existing myopia treatment strategy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 2 sitesSingapore
- Study dates
- 1 Dec 2026to 31 Dec 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 16 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Aged 8-16 years at enrolment.
- Cycloplegic spherical equivalent refraction between -3.00 and -20.00 dioptres.
- Astigmatism ≤6.00 dioptres.
- Documented poor response to conventional myopia-control treatment, defined as axial elongation ≥0.30 mm/year or myopia progression ≥0.50 dioptres/year in at least one eye despite treatment.
- Best-corrected visual acuity of 6/9 or better in both eyes.
- Informed consent obtained from a parent or guardian.
Who cannot join
- Orthokeratology lens use.
- Not currently receiving any myopia-control treatment.
- Ocular disease other than refractive error.
- Strabismus or a binocular vision disorder.
- Systemic disease affecting study participation.
- Contraindication to repeated low-level red-light therapy.
- Inability to attend follow-up visits.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Singapore2 sites
Singapore Eye Research Institute
Singapore
Singapore National Eye Centre
Singapore
About this study
Official title: Benefit of Repeated Illumination in Group of High Myopes and Treatment-resistant Cases (BRIGHT) - Repeated Low-Level Red Light (RLRL) Therapy (Evaluating RLRL Treatment in High Myopes and Non-Responders to Conventional Myopia Control) (BRIGHT-LIGHT)
Some children's short-sightedness (myopia) continues to worsen despite treatments such as atropine eye drops, myopia-control spectacles or contact lenses. These children may be at greater risk of developing severe short-sightedness and related eye problems later in life.
The BRIGHT-LIGHT study will assess the safety of repeated low-level red-light therapy and explore whether it can slow worsening short-sightedness in children whose myopia is inadequately controlled by conventional treatment. This therapy uses a device that delivers low-power red light to the eyes during short treatment sessions.
Read more
Forty children aged 8-16 years will be followed for 12 months: 30 receiving red-light therapy and 10 continuing conventional myopia treatment. Group assignment will depend on the willingness of children and their parents or guardians to start red-light therapy, rather than random allocation.
The main focus is safety, assessed through vision tests, detailed eye scans and tests of retinal function. The study will also assess changes in eye length and spectacle prescription to explore the treatment's effect on myopia progression.
Read the detailed description
Childhood myopia progression is largely associated with elongation of the eye. Although existing treatments can slow progression, some children continue to worsen despite treatment. Evidence on repeated low-level red-light (RLRL) therapy in children with an inadequate response to conventional myopia control remains limited.
BRIGHT-LIGHT is a prospective, non-randomised, open-label interventional cohort study with a concurrent control group. It is designed primarily to characterise safety and provide exploratory evidence of treatment response in this clinically important subgroup. A planned 3:1 allocation provides greater exposure to the intervention for safety assessment while retaining a comparator cohort receiving conventional care.
Participants who accept RLRL therapy will enter the intervention group. Those who decline RLRL therapy but agree to study follow-up will enter the control group and continue conventional myopia management. Participants using myopia-control spectacles or multifocal contact lenses may either continue these treatments alongside RLRL therapy or discontinue them when switching to RLRL therapy. Participants receiving atropine must discontinue atropine before starting RLRL therapy.
The study places particular emphasis on detecting possible retinal effects. Serial assessments will examine both retinal structure and function, alongside visual acuity and treatment-related symptoms. Retinal imaging and functional testing are intended to identify changes that may not be apparent from routine vision testing alone. Protocol-defined withdrawal criteria include a decrease in best-corrected visual acuity, retinal structural abnormalities or a serious adverse event. Participants who withdraw will undergo a safety evaluation.
Safety findings will be summarised descriptively. Longitudinal mixed-model analyses will evaluate changes in axial length and spherical equivalent refraction. Changes in choroidal thickness and retinal function will provide additional information about treatment response. The sample size is based on recruitment feasibility within the specialised clinical population, and the findings are intended to support exploratory and hypothesis-generating analyses.
- Conditions
- Myopia, Myopia Progressing, Myopia Progression, Light
- Being tested
- Repeated low-level red-light (RLRL) therapy, Continued existing myopia treatment strategy
- Keywords
- RLRL, Repeated low-level red light (RLRL) therapy, Myopia, Childhood myopia
- Medical subject headings
- Myopia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Repeated low-level red-light (RLRL) therapyDevice
Also called red light
Repeated low-level red-light (RLRL) therapy will be administered using the Eyerising Myopia Management Device, which delivers red light at a wavelength of 650 ± 10 nm and an output power of 2.0 ± 0.5 mW. Treatment consists of 3-minute sessions, twice per treatment day, separated by at least 4 hours, with a maximum of 10 sessions per week over 12 months. Participants may continue existing myopia-control spectacles or multifocal contact lenses alongside RLRL or switch to RLRL alone. Atropine eye drops must be discontinued before starting RLRL.
Continued existing myopia treatment strategyOther
Children are continued on existing myopia treatment strategy
| Study group | Role | What they receive |
|---|---|---|
| Repeated Low-Level Red-Light (RLRL) Therapy | Experimental | Participants will receive repeated low-level red-light (RLRL) therapy using the Eyerising Myopia Management Device for 12 months. Each session lasts 3 minutes, with two sessions per treatment day separated by at least 4 hours, up to 10 sessions per week. Participants using myopia-control spectacles or multifocal contact lenses may continue these treatments alongside RLRL or discontinue them and switch to RLRL alone. Participants receiving atropine eye drops must discontinue atropine before starting RLRL. Receives: Device: Repeated low-level red-light (RLRL) therapy |
| Conventional Myopia Management | Active comparator | Participants will continue conventional myopia-control treatment, such as atropine eye drops, myopia-control spectacles or multifocal contact lenses, without RLRL therapy. This concurrent control group will undergo study assessments over 12 months to allow comparison of safety findings and myopia progression with the RLRL group. Receives: Other: Continued existing myopia treatment strategy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Best-Corrected Visual Acuity
Change in best-corrected distance and near visual acuity, measured in logMAR units, to assess visual safety during treatment. A decrease of at least one line in best-corrected visual acuity meets the protocol-defined withdrawal criterion.
Measured: Baseline to 12 months, with assessments at 1, 3, 6 and 12 months.
Occurrence of Retinal Structural Abnormalities
Number and proportion of participants developing retinal structural abnormalities during follow-up. Retinal safety assessments include optical coherence tomography of the macula, fundus photography, fundus autofluorescence and optical coherence tomography angiography.
Measured: Throughout the 12-month study period.
Occurrence of Retinal Functional Abnormalities
Number and proportion of participants developing retinal functional abnormalities during follow-up. Assessments include colour vision, Amsler grid testing, contrast sensitivity, dark-adapted testing, microperimetry and multifocal electroretinography to detect potential retinal toxicity.
Measured: Throughout the 12-month study period.
Secondary outcomes (5)
Proportion of Participants Achieving Effective Myopia Control
Proportion of participants achieving effective myopia control after 12 months of RLRL therapy, assessed using axial elongation and spherical equivalent refractive progression.
Measured: At 12 months.
Change in Axial Length
Change in axial length, measured in millimetres, from baseline. Longitudinal changes will be evaluated using mixed-model analyses.
Measured: Baseline to 12 months, with measurements at 1, 3, 6 and 12 months.
Change in Spherical Equivalent Refraction
Change in cycloplegic spherical equivalent refraction, measured in dioptres, from baseline. Longitudinal changes will be evaluated using mixed-model analyses.
Measured: Baseline to 12 months, with measurements at 6 and 12 months.
Change in Choroidal Thickness
Change in choroidal thickness, measured using optical coherence tomography, from baseline to assess the anatomical response to treatment.
Measured: Baseline to 12 months, with measurements at 1, 3, 6 and 12 months.
Change in Retinal Function
Changes in retinal function assessed using contrast sensitivity, dark-adapted testing, microperimetry and multifocal electroretinography.
Measured: - Through 12 months, according to the protocol-specified assessment schedule.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2026
- Study start1 Dec 2026 (estimated)
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for MyopiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Model description
- This prospective, non-randomised study uses a parallel-group model with a concurrent control group. Participants will be allocated according to their willingness to receive repeated low-level red-light (RLRL) therapy, with a planned 3:1 ratio: 30 receiving RLRL therapy and 10 continuing conventional myopia management. Participants using myopia-control spectacles or multifocal contact lenses may continue these treatments alongside RLRL or switch to RLRL alone. Atropine must be discontinued before starting RLRL. Both groups will be followed for 12 months. The study is open-label, with no masking.
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Singapore National Eye Centre
- Sponsor type
- Other government
- Collaborators
- Singapore Eye Research Institute
- Responsible party
- Principal investigator, Bryan Sim XR, Singapore National Eye Centre
- Investigators
- Bryan XR Sim, MD FRCOphth, Principal investigator, Singapore National Eye Centre (SNEC)/Singapore Eye Research Institute (SERI)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07923019
- Sponsor's protocol ID
- SingaporeNEC_RLRL
- Other IDs
- 2026-0840
- Acronym
- BRIGHT LIGHT
- Status last verified
- Nov 2026
- First submitted
- 2 Nov 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There are currently no plans to share individual participant data with other researchers. Study findings will be disseminated through peer-reviewed publications in aggregate form, without identifying individual participants.
Publications
1. He M, Zeng J, Liu Y, Xu J, Pokharel GP, Ellwein LB. Refractive error and visual impairment in urban children in southern China. Invest Ophthalmol Vis Sci 2004;45(3):793-9. 2. Lin LL, Shih YF, Hsiao CK, Chen CJ. Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000. Ann Acad Med Singap 2004;33(1):27-33. 3. Wang H, Li Y, Qiu K, et al. Prevalence of myopia and uncorrected myopia among 721,032 schoolchildren in southern China: the Shantou Myopia Study. Br J Ophthalmol 2022. 4. Hashemi H, Rezvan F, Ostadimoghaddam H, Abdollahi M, Hashemi M, Khabazkhoob M. High prevalence of refractive errors in a rural population. Clin Exp Ophthalmol 2013;41(7):635-43. 5. Sun J, Zhou J, Zhao P, et al. High prevalence of myopia in Chinese university students. Invest Ophthalmol Vis Sci 2012;53(12):7504-9. 6. Pan CW, Zheng YF, Anuar AR, et al. Prevalence of refractive errors in a multiethnic Asian population. Invest Ophthalmol Vis Sci 2013;54(4):2590-8. 7. Wang TJ, Chiang TH, Wang TH, Lin LL, Shih YF. Changes of ocular refraction in Taiwan university students. Eye (Lond) 2009;23(5):1168-9. 8. Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia (2000-2050). Ophthalmology 2016;123(5):1036-42. 9. GBD Vision Loss Expert Group. Causes of blindness and vision impairment in 2020. Lancet Glob Health 2021;9(2):e144-e160. 10. Fricke TR, Holden BA, Wilson DA, et al. Global cost of correcting vision impairment. Bull World Health Organ 2012;90(10):728-38. 11. Flitcroft DI, He M, Jonas JB, et al. IMI-Defining and classifying myopia. Invest Ophthalmol Vis Sci 2019;60(3):M20-M30. 12. Ikuno Y. Complications of high myopia. Retina 2017;37(12):2347-51. 13. Bullimore MA, Brennan NA. Myopia control: why each diopter matters. Optom Vis Sci 2019;96(6):463-5. 14. Gong Q, Janowski M, Luo M, et al. Atropine in childhood myopia: meta-analysis. JAMA Ophthalmol 2017;135(6):624-30. 15. Sun Y, Xu F, Zhang T, et al. Orthokeratology for myopia control: meta-analysis
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Benefit of Repeated Illumination in Group of High Myopes and Treatment-resistant Cases (BRIGHT) - Repeated Low-Level Red Light (RLRL) Therapy (Evaluating RLRL Treatment in High Myopes and Non-Responders to Conventional Myopia Control) (BRIGHT-LIGHT)
- ClinicalTrials.gov ID
- NCT07923019
- Acronym / sponsor ID
- BRIGHT LIGHT / SingaporeNEC_RLRL
- Conditions
- Myopia, Myopia Progressing, Myopia Progression, Light
- Keywords
- RLRL, Repeated low-level red light (RLRL) therapy, Myopia, Childhood myopia
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Singapore National Eye CentreOther government
- Collaborators
- Singapore Eye Research Institute
- Study start
- 1 Dec 2026 (estimated)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 31 Dec 2031 (estimated)
- First posted
- 6 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Some children's short-sightedness (myopia) continues to worsen despite treatments such as atropine eye drops, myopia-control spectacles or contact lenses. These children may be at greater risk of developing severe short-sightedness and related eye problems later in life.
The BRIGHT-LIGHT study will assess the safety of repeated low-level red-light therapy and explore whether it can slow worsening short-sightedness in children whose myopia is inadequately controlled by conventional treatment. This therapy uses a device that delivers low-power red light to the eyes during short treatment sessions.
Forty children aged 8-16 years will be followed for 12 months: 30 receiving red-light therapy and 10 continuing conventional myopia treatment. Group assignment will depend on the willingness of children and their parents or guardians to start red-light therapy, rather than random allocation.
The main focus is safety, assessed through vision tests, detailed eye scans and tests of retinal function. The study will also assess changes in eye length and spectacle prescription to explore the treatment's effect on myopia progression.
Detailed description
Childhood myopia progression is largely associated with elongation of the eye. Although existing treatments can slow progression, some children continue to worsen despite treatment. Evidence on repeated low-level red-light (RLRL) therapy in children with an inadequate response to conventional myopia control remains limited.
BRIGHT-LIGHT is a prospective, non-randomised, open-label interventional cohort study with a concurrent control group. It is designed primarily to characterise safety and provide exploratory evidence of treatment response in this clinically important subgroup. A planned 3:1 allocation provides greater exposure to the intervention for safety assessment while retaining a comparator cohort receiving conventional care.
Participants who accept RLRL therapy will enter the intervention group. Those who decline RLRL therapy but agree to study follow-up will enter the control group and continue conventional myopia management. Participants using myopia-control spectacles or multifocal contact lenses may either continue these treatments alongside RLRL therapy or discontinue them when switching to RLRL therapy. Participants receiving atropine must discontinue atropine before starting RLRL therapy.
The study places particular emphasis on detecting possible retinal effects. Serial assessments will examine both retinal structure and function, alongside visual acuity and treatment-related symptoms. Retinal imaging and functional testing are intended to identify changes that may not be apparent from routine vision testing alone. Protocol-defined withdrawal criteria include a decrease in best-corrected visual acuity, retinal structural abnormalities or a serious adverse event. Participants who withdraw will undergo a safety evaluation.
Safety findings will be summarised descriptively. Longitudinal mixed-model analyses will evaluate changes in axial length and spherical equivalent refraction. Changes in choroidal thickness and retinal function will provide additional information about treatment response. The sample size is based on recruitment feasibility within the specialised clinical population, and the findings are intended to support exploratory and hypothesis-generating analyses.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This prospective, non-randomised study uses a parallel-group model with a concurrent control group. Participants will be allocated according to their willingness to receive repeated low-level red-light (RLRL) therapy, with a planned 3:1 ratio: 30 receiving RLRL therapy and 10 continuing conventional myopia management. Participants using myopia-control spectacles or multifocal contact lenses may continue these treatments alongside RLRL or switch to RLRL alone. Atropine must be discontinued before starting RLRL. Both groups will be followed for 12 months. The study is open-label, with no masking.
| Arm | Type | Receives |
|---|---|---|
| Repeated Low-Level Red-Light (RLRL) Therapy | Experimental | Device: Repeated low-level red-light (RLRL) therapyParticipants will receive repeated low-level red-light (RLRL) therapy using the Eyerising Myopia Management Device for 12 months. Each session lasts 3 minutes, with two sessions per treatment day separated by at least 4 hours, up to 10 sessions per week. Participants using myopia-control spectacles or multifocal contact lenses may continue these treatments alongside RLRL or discontinue them and switch to RLRL alone. Participants receiving atropine eye drops must discontinue atropine before starting RLRL. |
| Conventional Myopia Management | Active comparator | Other: Continued existing myopia treatment strategyParticipants will continue conventional myopia-control treatment, such as atropine eye drops, myopia-control spectacles or multifocal contact lenses, without RLRL therapy. This concurrent control group will undergo study assessments over 12 months to allow comparison of safety findings and myopia progression with the RLRL group. |
Who may qualify
- Ages
- 8 to 16 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (6 listed)
- Aged 8-16 years at enrolment.
- Cycloplegic spherical equivalent refraction between -3.00 and -20.00 dioptres.
- Astigmatism ≤6.00 dioptres.
- Documented poor response to conventional myopia-control treatment, defined as axial elongation ≥0.30 mm/year or myopia progression ≥0.50 dioptres/year in at least one eye despite treatment.
- Best-corrected visual acuity of 6/9 or better in both eyes.
Key exclusion criteria (7 listed)
- Orthokeratology lens use.
- Not currently receiving any myopia-control treatment.
- Ocular disease other than refractive error.
- Strabismus or a binocular vision disorder.
- Systemic disease affecting study participation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Repeated low-level red-light (RLRL) therapyAlso: red lightRepeated low-level red-light (RLRL) therapy will be administered using the Eyerising Myopia Management Device, which delivers red light at a wavelength of 650 ± 10 nm and an output power of 2.0 ± 0.5 mW. Treatment consists of 3-minute sessions, twice per treatment day, separated by at least 4 hours, with a maximum of 10 sessions per week over 12 months. Participants may continue existing myopia-control spectacles or multifocal contact lenses alongside RLRL or switch to RLRL alone. Atropine eye drops must be discontinued before starting RLRL. | Device | Repeated Low-Level Red-Light (RLRL) Therapy |
| Continued existing myopia treatment strategyChildren are continued on existing myopia treatment strategy | Other | Conventional Myopia Management |
Primary outcome
Change in Best-Corrected Visual Acuity
Time frame: Baseline to 12 months, with assessments at 1, 3, 6 and 12 months.
Change in best-corrected distance and near visual acuity, measured in logMAR units, to assess visual safety during treatment. A decrease of at least one line in best-corrected visual acuity meets the protocol-defined withdrawal criterion.
Occurrence of Retinal Structural Abnormalities
Time frame: Throughout the 12-month study period.
Number and proportion of participants developing retinal structural abnormalities during follow-up. Retinal safety assessments include optical coherence tomography of the macula, fundus photography, fundus autofluorescence and optical coherence tomography angiography.
Occurrence of Retinal Functional Abnormalities
Time frame: Throughout the 12-month study period.
Number and proportion of participants developing retinal functional abnormalities during follow-up. Assessments include colour vision, Amsler grid testing, contrast sensitivity, dark-adapted testing, microperimetry and multifocal electroretinography to detect potential retinal toxicity.
5 secondary outcomes
Proportion of Participants Achieving Effective Myopia Control
Time frame: At 12 months.
Change in Axial Length
Time frame: Baseline to 12 months, with measurements at 1, 3, 6 and 12 months.
Change in Spherical Equivalent Refraction
Time frame: Baseline to 12 months, with measurements at 6 and 12 months.
Change in Choroidal Thickness
Time frame: Baseline to 12 months, with measurements at 1, 3, 6 and 12 months.
Change in Retinal Function
Time frame: - Through 12 months, according to the protocol-specified assessment schedule.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Background1. He M, Zeng J, Liu Y, Xu J, Pokharel GP, Ellwein LB. Refractive error and visual impairment in urban children in southern China. Invest Ophthalmol Vis Sci 2004;45(3):793-9. 2. Lin LL, Shih YF, Hsiao CK, Chen CJ. Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000. Ann Acad Med Singap 2004;33(1):27-33. 3. Wang H, Li Y, Qiu K, et al. Prevalence of myopia and uncorrected myopia among 721,032 schoolchildren in southern China: the Shantou Myopia Study. Br J Ophthalmol 2022. 4. Hashemi H, Rezvan F, Ostadimoghaddam H, Abdollahi M, Hashemi M, Khabazkhoob M. High prevalence of refractive errors in a rural population. Clin Exp Ophthalmol 2013;41(7):635-43. 5. Sun J, Zhou J, Zhao P, et al. High prevalence of myopia in Chinese university students. Invest Ophthalmol Vis Sci 2012;53(12):7504-9. 6. Pan CW, Zheng YF, Anuar AR, et al. Prevalence of refractive errors in a multiethnic Asian population. Invest Ophthalmol Vis Sci 2013;54(4):2590-8. 7. Wang TJ, Chiang TH, Wang TH, Lin LL, Shih YF. Changes of ocular refraction in Taiwan university students. Eye (Lond) 2009;23(5):1168-9. 8. Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia (2000-2050). Ophthalmology 2016;123(5):1036-42. 9. GBD Vision Loss Expert Group. Causes of blindness and vision impairment in 2020. Lancet Glob Health 2021;9(2):e144-e160. 10. Fricke TR, Holden BA, Wilson DA, et al. Global cost of correcting vision impairment. Bull World Health Organ 2012;90(10):728-38. 11. Flitcroft DI, He M, Jonas JB, et al. IMI-Defining and classifying myopia. Invest Ophthalmol Vis Sci 2019;60(3):M20-M30. 12. Ikuno Y. Complications of high myopia. Retina 2017;37(12):2347-51. 13. Bullimore MA, Brennan NA. Myopia control: why each diopter matters. Optom Vis Sci 2019;96(6):463-5. 14. Gong Q, Janowski M, Luo M, et al. Atropine in childhood myopia: meta-analysis. JAMA Ophthalmol 2017;135(6):624-30. 15. Sun Y, Xu F, Zhang T, et al. Orthokeratology for myopia control: meta-analysis
- Individual participant dataSharing planned: No. There are currently no plans to share individual participant data with other researchers. Study findings will be disseminated through peer-reviewed publications in aggregate form, without identifying individual participants.
Related trials for Myopia
Active, not recruiting
Effect of IOP Lowering on Progressive HM
High Myopia, Intraocular Pressure
Recruiting
Evaluation of a New Laser Refractive Vision Correction Using the TENEO™ 317 Model 2
Hyperopia and Myopia
Recruiting
Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses
Myopia, Myopia Progression
Not yet recruiting
Clinical Performance and Outcomes After Toric Lens Transition
Astigmatism
Not yet recruiting
The EYERISING Study
Myopia, Astigmatism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Bryan XR Sim, MD FRCOphth principal investigator
Singapore National Eye Centre (SNEC)/Singapore Eye Research Institute (SERI)
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Repeated low-level red-light (RLRL) therapy and Continued existing myopia treatment strategy in people with Myopia and Myopia Progressing, run by Singapore National Eye Centre at 2 sites in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rong Qiang Chua, MSc (65767200, chua.rong.qiang@seri.com.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Best-Corrected Visual Acuity (time frame: Baseline to 12 months, with assessments at 1, 3, 6 and 12 months.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07923019, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.